ibandronate + vitamin D (Shinshu University)

ibandronate + vitamin D is a combination therapy being investigated by **Shinshu University** for the treatment of primary and secondary osteoporosis. **Ibandronate** is a nitrogen-containing bisphosphonate that acts by inhibiting **farnesyl pyrophosphate synthase (FPPS)** within osteoclasts. This inhibition disrupts the mevalonate pathway, leading to osteoclast apoptosis and a subsequent reduction in bone resorption, which helps maintain or increase bone mineral density. The combination includes an **active vitamin D** analogue (such as alfacalcidol or calcitriol), which serves as an agonist for the **vitamin D receptor (VDR)**. This component enhances intestinal calcium absorption and regulates bone turnover, potentially providing a synergistic effect when administered alongside bisphosphonates. This specific regimen is being evaluated in Phase 2 clinical trials to compare its efficacy against ibandronate monotherapy in Japanese patient populations.

Other names

oral ibandronate and vitamin Dibandronate sodium + vitamin Dibandronate + active vitamin D